"median overall survival was 15.2 and 15.5 months for ITT and PP populations, respectively." -Ross P.J, Wasan H.S, Croagh D et. al. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy, ESMO Open, 2021, 7(1) https://doi.org/10.1016/j.esmoop.2021.100356
Do you really think they would be able to sell a product that could potentially only increase life by 0.3months for nonresectable pancreatic cancer patients? And I would argue that the sample size isn't even strong enough to be able to suggest it increases life by 0.3months since it is less than 50patients.
Figure 1. Participant flow in the PanCO study adapted from -Ross P.J, Wasan H.S, Croagh D et. al. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy, ESMO Open, 2021, 7(1) https://doi.org/10.1016/j.esmoop.2021.100356
If the company is trying to suggest it is COVID stopping the sale of this product, then people should just really read the science this product is based on.
OSL Price at posting:
4.6¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)